Griseofulvin
An antifungal medication taken orally to treat fungal infections of the skin, hair, and nails, working by interfering with fungal cell division and disrupting the microtubule structure that fungi need to reproduce. Treatment typically requires several weeks to months depending on the site of infection. It has also been investigated for potential anticancer properties in cell growth studies.
Molecular Weight
352.8000 g/mol
LogP
2.20
TPSA
71.10 Ų
Lipinski RO5
Pass
Therapeutic Areas
Mechanism of Action
Disrupts microtubule dynamics by binding to tubulin, preventing the formation of the mitotic spindle and arresting cell division at metaphase. This induces apoptosis in rapidly dividing cells.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Disrupts microtubule dynamics by binding to tubulin, preventing the formation of the mitotic spindle and arresting cell division at metaphase. This induces apoptosis in rapidly dividing cells.
2D Structure
Cite this structure
Embed this structure
SMILES
COC1=CC(=O)C[C@@H](C)[C@]12Oc1c(Cl)c(OC)cc(OC)c1C2=O
InChI
InChI=1S/C17H17ClO6/c1-8-5-9(19)6-12(23-4)17(8)16(20)13-10(21-2)7-11(22-3)14(18)15(13)24-17/h6-8H,5H2,1-4H3/t8-,17+/m1/s1
Molecular Formula
C17H17ClO6
HBD / HBA
- / 6
Rotatable Bonds
3
Heavy Atoms
24
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Frequently Asked Questions
An antifungal medication taken orally to treat fungal infections of the skin, hair, and nails, working by interfering with fungal cell division and disrupting the microtubule structure that fungi need to reproduce. Treatment typically requires several weeks to months depending on the site of infection. It has also been investigated for potential anticancer properties in cell growth studies.
Disrupts microtubule dynamics by binding to tubulin, preventing the formation of the mitotic spindle and arresting cell division at metaphase. This induces apoptosis in rapidly dividing cells.
Yes, Griseofulvin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL562. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 441140. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="griseofulvin"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/griseofulvin/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/griseofulvin/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/griseofulvin/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="griseofulvin"></drugfyi-drug>